NASDAQ:YMAB

Delisted

Y-mabs Therapeutics Stock News

Healthcare > Biotechnology

Buy YMAB

*Your capital is at risk

$8.61

+0 (+0%)

At Close: Dec 15, 2025

Y-mAbs Therapeutics: A Yawn From The Market Means Opportunity

04:35pm, Friday, 11'th Apr 2025

YMAB's naxitamab shows a 50% overall response rate in phase 2 trials for high-risk neuroblastoma, supporting its ongoing commercialization efforts. The SADA platform, targeting GD2 and CD38, is YMAB's

Y-mAbs Therapeutics, Inc. (YMAB) Q4 2024 Earnings Call Transcript

03:03pm, Tuesday, 04'th Mar 2025

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB ) Q4 2024 Earnings Conference Call March 4, 2025 8:00 AM ET Company Participants Courtney Dugan - Head-IR Michael Rossi - President & CEO Doug Gentilcore - Senio

Y-mAbs Therapeutics, Inc. (YMAB) Reports Q4 Loss, Lags Revenue Estimates

08:45am, Tuesday, 04'th Mar 2025

Y-mAbs Therapeutics, Inc. (YMAB) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to loss of $0.02 per share a year ago.

Y-mAbs Reports Fourth Quarter 2024 Financial Results and Recent Corporate Developments

06:35am, Tuesday, 04'th Mar 2025

Reported Total Revenues of $26.5 million for the fourth quarter of 2024 and $87.7 million for the full year 2024 The Company established two business units in January 2025 aimed to accelerate the clin

Y-mAbs Announces Publication of Phase 2 Interim Results in Nature Communications

07:30am, Monday, 03'rd Mar 2025

Naxitamab demonstrated clinically meaningful efficacy with manageable safety in patients with relapsed/refractory high-risk neuroblastoma and residual disease in bone/bone marrow Naxitamab demonstrate

Y-mAbs Therapeutics, Inc. (YMAB) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

11:00am, Tuesday, 25'th Feb 2025

YmAbs Therapeutics (YMAB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Y-mAbs to Announce Fourth Quarter and Full Year 2024 Financial and Operating Results on March 4, 2025

04:05pm, Thursday, 20'th Feb 2025

NEW YORK, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and co

Y-mAbs to Present at the Oppenheimer 35ᵗʰ Annual Life Sciences Conference

07:30am, Thursday, 06'th Feb 2025

NEW YORK, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and co

YmAbs Therapeutics (YMAB) Loses -25.74% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

10:36am, Tuesday, 04'th Feb 2025

The heavy selling pressure might have exhausted for YmAbs Therapeutics (YMAB) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street

YmAbs Therapeutics (YMAB) Loses -26.93% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

10:35am, Monday, 03'rd Feb 2025

YmAbs Therapeutics (YMAB) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings

Y-mAbs Presents Translational Pharmacokinetics of GD2-SADA from Pretargeted RIT Platform at the SNMMI Mid-Winter and ACNM Annual Meeting

07:35am, Friday, 31'st Jan 2025

NEW YORK, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and co

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by